Document is current
Any future updates will be listed below
-
Authors
Morshedi Rad, Dorsa
Richards, Claire
Zhand, Sareh
de Alwis, Natasha
Hannan, Natalie J
Faiz, Alen https://orcid.org/0000-0003-1740-3538
McClements, Lana https://orcid.org/0000-0002-4911-1014
Ebrahimi Warkiani, Majid https://orcid.org/0000-0002-4184-1944
-
Funding
Funding for this research was provided by:
National Heart Foundation of Australia (106628)
Department of Education and Training | Australian Research Council (DP200101860)
Cancer Institute NSW (2021CDF1148)
- License Information
-
More Information
Article History
Received: 3 April 2025
Revised: 21 October 2025
Accepted: 30 October 2025
First Online: 24 November 2025
Competing interests
: The authors declare no conflict of interest. LM is an inventor on FKBPL -related patents for preeclampsia.
: Ethical approval for this project was obtained from Mercy Health Human Research Ethics Committee (R11/34) and Austin Health Human Research Ethics Committee (HREC/18/Austin/44). Participants provided informed, written consent for sample collection. Experiments were performed following institutional guidelines and regulations. Appropriate biosafety and human research ethics approvals related to the use of CRISPR technology and ACH-3P cell line were also obtained from the University of Technology Sydney.
: All the authors have consented for publication in the journal.
